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Purpose: We analyzed the prescriptions of alpha-blockers and phosphodiesterase 5 inhibitors (PDE5Is) in the urology depart-
ment as well as in other departments of the general hospital.
Methods: We investigated the frequency of prescription of alpha-blockers and PDE5Is from 3 general hospitals from January 1, 
2007 to December 31, 2009. For alpha-blockers, data were collected from patients to whom alpha-blockers were prescribed 
from among patients recorded as having benign prostatic hyperplasia according to the 5th Korean Standard Classification of 
Diseases. For PDE5Is, data were collected from patients to whom PDE5Is were prescribed by the urology department and by 
other departments. Alpha-blockers were classified into tamsulosin, alfuzosin, doxazosin, and terazosin, whereas PDE5Is were 
classified into sildenafil, tadalafil, vardenafil, udenafil, and mirodenafil.
Results: Alpha-blockers were prescribed to 11,436 patients in total over 3 years, and the total frequency of prescriptions was 
68,565. Among other departments, the nephrology department had the highest frequency of prescription of 3,225 (4.7%), fol-
lowed by the cardiology (3,101, 4.5%), neurology (2,576, 3.8%), endocrinology (2,400, 3.5%), pulmonology (1,102, 1.6%), and 
family medicine (915, 1.3%) departments in order. PDE5Is were prescribed to 2,854 patients in total over 3 years, and the total 
frequency of prescriptions was 10,558. The prescription frequency from the urology department was 4,900 (46.4%). Among 
other departments, the endocrinology department showed the highest prescription frequency of 3,488 (33.0%), followed by the 
neurology (542, 5.1%), cardiology (467, 4.4%), and family medicine (407, 3.9%) departments in order.
Conclusions: A high percentage of prescriptions of alpha-blockers and PDE5Is were from other departments. For more special-
ized medical care by urologists is required in the treatment of lower urinary tract symptoms and erectile dysfunction.
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INTRODUCTION
Adrenergic alpha-1 receptor antagonists (alpha blockers) and 
phosphodiesterase 5 inhibitors (PDE5Is) are the first-line treat-
ment for lower urinary tract symptoms (LUTS) as well as erec-
tile dysfunction (ED) [1]. For benign prostatic hyperplasia 
(BPH) accompanied by LUTS, the European Association of 
Urology encourages the pretreatment recommended assessment 
to include a medical history, symptom score, prostate-specific 
antigen (PSA) measurement, physical examination including a 
digital rectal examination, serum creatinine, urinalysis, flow 
rate, and post-voided residual urine (PVR) [2]. For ED, a basic 
workup should be performed, primarily including identifica-
tion of the presence of hypertension, diabetes mellitus, myocar-
dial disease, lipidemia, hypercholesterolemia, renal insufficien-
cy, hypogonadism, neurologic disorders, and psychiatric disor-
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ders [3]. For the determination of the causes of ED after the ba-
sic workup, vascular studies, neurologic studies, endocrinologic 
studies, and specialized psychodiagnostic evaluation shall be 
performed for nocturnal penile tumescence and rigidity using 
Rigiscan, intracavernous vasoactive drug injection, and duplex 
ultrasound of the cavernous arteries. Both LUTS/BPH and ED 
can be assessed according to symptoms and treatment results 
by urological evaluation and questionnaires such as the Inter-
national Prostate Symptom Score (IPSS), Overactive Bladder 
Symptom Scores, International Index of Erectile Function (IIEF), 
and the Sexual Health Inventory for Men for basic workup on a 
regular basis [4,5].
  Thus, the pretreatment assessments of BPH/LUTS and ED 
are complicated and require prescriptions of alpha-blockers and 
PDE5Is, which are the primary therapeutic agents prescribed 
after the assessments are completed by use of the various uro-
logical diagnostic tools. A physician’s lack of urologic knowledge 
can result in poor adherence. So far, there have been no reports 
in Korea on the actual prescription of alpha-blockers and 
PDE5Is by clinical departments other than the urology depart-
ment. In the present study, therefore, the authors analyzed the 
prescriptions of alpha-blockers and PDE5Is in the treatment of 
BPH/LUTS and ED in outpatient medical examinations in the 
urology department as well as in other departments of the gen-
eral hospital and considered the problems caused by the use of 
these agents by other departments.
MATERIALS AND METHODS
For this study, an investigation was conducted on the frequency 
of prescription of alpha-blockers and PDE5Is from 3 general 
hospitals from January 1, 2007 to December 31, 2009. For al-
pha-blockers, the data were collected from patients to whom 
alpha-blockers were prescribed from among patients recorded 
as having benign prostatic hyperplasia according to the 5th Ko-
rean Standard Classification of Diseases. For PDE5Is, the data 
were collected from patients to whom PDE5Is were prescribed 
by the urology department and by other departments. The pe-
riod of data collection and analysis was from July 2010 to June 
2011. Alpha-blockers were classified into tamsulosin, alfuzosin, 
doxazosin, and terazosin, whereas PDE5Is were classified into 
sildenafil, tadalafil, udenafil, vardenafil, and mirodenafil. The 
ages of the patients prescribed the above drugs for 3 years, the 
prescription frequency for the same patient, and the mean 
number of pills prescribed for a one-time dose were analyzed 
according to drug. The data collected included the prescription 
records of all 3 general hospitals for 3 years.
  Sample data were analyzed with descriptive analysis, using 
Open Office.org Calc (Open Office.org ver. 3.2.0, Oracle Co., 
Redwood Shores, CA, USA), and with the chi-square test using 
MedCalc (MedCalc ver. 11.2.1.0, MedCalc Software, Mariaker-
ke, Belgium). For the statistical analysis, P-values less than 0.05 
were considered statistically significant.
RESULTS
Alpha-Blockers
Alpha-blockers were prescribed to 11,436 patients in total over 
3 years, and the total frequency of prescriptions was 68,565. The 
mean frequency of prescription in the same patient was 5.54 
(range, 1 to 63) times, and the mean age of the patients was 
64.12±11.12 years old. The prescription frequency from the 
urology department was 52,220 times (76.2%). The nephrology 
department showed the next highest frequency of prescription 
of 3,225 (4.7%), followed by the cardiology department (3,101, 
4.5%), the neurology department (2,576, 3.8%), the endocrinol-
ogy department (2,400, 3.5%), the pulmonology department 
(1,102, 1.6%), and the family medicine department (915, 1.3%) 
in order (Fig. 1). The prescription frequency by drug was as fol-
lows: tamsulosin, 34,212 (49.9%); alfuzosin, 17,714 (25.8%); 
doxazosin, 10,980 (16.0%); and terazosin, 5,659 (8.3%). The 
prescription frequency from the urology department was as 
follows: tamsulosin, 27,195 (52.1%); alfuzosin, 11,124 (21.3%); 
doxazosin, 9,450 (18.1%); and terazosin, 4,451 (8.5%). Drugs 
prescribed from the other departments showed the same order 
of frequency as did the urology department as follows: tamsu-
losin, 7,017 (42.9%); alfuzosin, 6,590 (40.3%); doxazosin, 1,530 
(9.4%); and terazosin, 1,208 (7.4%). The prescription frequency 
between the urology department and the other departments 
showed statistically significant differences, however (P<0.001) 
(Fig. 2).
  Over the 3 years studied, the prescriptions of tamsulosin 
from all hospitals were 10,864 (2007), 10,959 (2008), and 12,389 
(2009), and there were no significant differences (Fig. 3A). Over 
the 3 years studied, the prescriptions of tamsulosin versus alfu-
zosin from departments other than the urology department 
were 2,546 vs. 2,042 (2007), 2,263 vs. 1,977 (2008), and 2,208 vs. 
2,571 (2009) (Fig. 3B).218    www.einj.or.kr
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Phosphodiesterase 5 Inhibitors 
PDE5Is were prescribed to 2,854 patients in total over 3 years, 
and the total frequency of prescriptions was 10,558. The mean 
age of the patients was 58.36±0.10 years, and the mean frequen-
cy of prescription in the same patient was 3.70 (range, 1 to 36) 
times with the mean number of pills prescribed for a one-time 
dose being 7.54±0.17. The prescription frequency from the 
urology department was 4,900 (46.4%). Among other depart-
ments, the endocrinology department showed the highest pre-
scription frequency of 3,488 (33.0%), followed by the neurology 
department (542, 5.1%), the cardiology department (467, 4.4%), 
and the family medicine department (407, 3.9%) in order (Fig. 
4). The prescription frequency by drug was as follows: sildena-
fil, 4,345 (41.2%); tadalafil, 2,518 (23.8%); udenafil, 2,301 
Fig. 1. Comparison of prescription of alpha-blockers for 3 years. UR, urology; NE, nephrology; CV, cardiology; NR, neurology; EM, 
endocrinology; CM, pulmonology; FM, family medicine; RE, rehabilitation medicine; NS, neurosurgery; GE, gastroenterology; ER, 
emergency medicine; RM, rheumatology; HO, hemato-oncology; TS, chest surgery; NP, neuropsychiatrics; GS, general surgery; OS, 
orthopaedic surgery; ID, infectious disease; OL, otolaryngology; DM, dermatology.
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Fig. 3. Yearly variations in the prescription of alpha-blockers (A) 
From all departments; (B) From departments other than the 
urology department.
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as follows: sildenafil, 1,758 (35.9%); tadalafil, 1,403 (28.6%); 
udenafil, 763 (15.6%); vardenafil, 707 (14.4%); and mirodenafil, 
269 (5.5%). The frequency of prescription of drugs by the other 
departments was as follows: sildenafil, 2,587 (45.7%); udenafil, 
1,538 (27.2%); tadalafil, 1,115 (19.7%); vardenafil, 277 (4.9%); 
and mirodenafil, 141(2.5%). The prescription frequency be-
tween the urology department and the other departments 
showed statistically significant differences (P<0.001) (Fig. 5).
  In the 3 years studied, prescriptions of tadalafil from all hos-
pitals surpassed those of udenafil in 2009 (1,126 vs. 738), where-
as no substantial differences in the prescription of sildenafil were 
shown (1,423 in 2007, 1,473 in 2008, and 1,449 in 2009) (Fig. 
6A). Concerning the prescription of PDE5Is from departments 
Fig. 4. Comparison of prescription of phosphodiesterase 5 inhibitors for 3 years. UR, urology; EM, endocrinology; NR, neurology; 
CV, cardiology; GE, gastroenterology; NE, nephrology; RM, rheumatology; NP, neuropsychiatrics; TS, chest surgery; PD, pediatrics; 
NS, neurosurgery; OG, obsterics-gynecology; RE, rehabilitation medicine; GS, general surgery; CM, pulmonology; OS, orthopaedic 
surgery; DM, dermatology; OT, ophthalmology; ER, emergency medicine; ID, infectious disease; RT, therapeutic radiology; SP, pedi-
atric surgery.
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other than the urology department over the 3 years studied, 
udenafil was prescribed at a higher percentage compared with 
tadalafil each year, unlike the result for all hospitals combined 
(Fig. 6B).
DISCUSSION
Medical adherence (the degree to which a patient follows the 
recommendations of health professionals) is a salient outcome 
of the process of care. Poor adherence is affected by patient-re-
lated, physician-related, and health system/team building-relat-
ed factors [6]. In particular, physician-related factors are ground-
ed on a good physician-patient relationship and play an impor-
tant role in increasing medical adherence [7]. The ways in which 
physicians contribute to patients’ poor adherence include fail-
ing to explain the benefits and side effects of a medication ade-
quately, not giving consideration to the patient’s lifestyle or the 
cost of the medications, and having poor therapeutic relation-
ships with patients [8-10]. According to a meta-analysis con-
ducted by Zolnierek and Dimatteo [11] that analyzed 127 piec-
es of literature, communication and medical adherence had a 
higher correlation depending on whether the physician was a 
specialist or not (r=2.2, P=0.022). To this end, it is considered 
that the relationship, communication, and detailed explanation 
by the physician play important roles in increasing medical ad-
herence in the treatment of chronic disease.
  In the field of urology, Collins et al. [12] reported on the dif-
ferences in practice patterns of 444 primary care physicians 
(PCPs) and 394 urologists in the United States in the diagnosis 
and treatment in 1997 in compliance with the 1994 version of 
the Agency for Health Care Policy and Research BPH guide-
lines. Among PCPs and urologists, respectively, approximately 
18% and 63% had routinely conducted the American Urologi-
cal Association symptom scoring, respectively, whereas 1% and 
40% had conducted uroflowmetry and 3% and 39% had per-
formed routine PVR identification with use of ultrasonography. 
These differences were statistically significant. In that study, the 
authors analyzed the practice patterns of PCPs who had been 
trained in the diagnosis and treatment of BPH according to the 
guidelines; therefore, no direct comparison can be made with 
the diagnostic tools being used by physicians of other depart-
ments in Korea when they prescribe alpha-blockers. Neverthe-
less, it is possible to see that PCPs in the United States also show 
lower percentages statistically in the use of recommended diag-
nostic tools compared with urologists. In 2004, Seftel et al. [13] 
also conducted a comparative study on the practice patterns of 
351 PCPs and 437 urologists in the United States for patients 
with BPH/LUTS and sexual dysfunction. Among PCPs, only 
41% had used the IPSS for the evaluation of LUTS, whereas 
97% of urologists had used it for the same purpose. Conversely, 
26% of PCPs had used BPH medication, whereas 21% of urolo-
gists had used it. The authors concluded that more systematic 
education is required for PCPs on the diagnosis and treatment 
of patients with BPH. According to recently reported research, 
the IPSS is being used as an initial diagnostic test for BPH by 
98% of Korean urologists in general hospitals and by 73.3% in 
private urologic clinics in comparison with uroflowmetry, 
which was used by 90.0% and by 50.0%, respectively [14]. This 
result was similar to the results for urologists from the research 
of Seftel et al. [13], which makes it possible to infer that diagno-
sis and treatment by clinicians other than urologists may be in-
sufficient.
  Rutchik et al. [15] reported on the practice patterns of family 
practitioners for ED. They reported that 84% of family practi-
tioners carried out history taking as well as physical examina-
tion and approximately 60% of them performed hormone and 
chemical laboratory tests, but only 2 to 3% of them performed 
Rigiscan or penile Doppler ultrasound. In 2006, Young et al. [16] 
reported the interesting results of their analysis of the sildenafil-
prescribing patterns of urologists and physicians of family medi-
cine as well as internal medicine by use of data from the Na-
tional Center for Health Statistics in the United States. Urolo-
gists documented erectile or psychosexual dysfunction signifi-
cantly more often than did family medicine, internal medicine, 
and other physicians (P=0.003). Those results, which presented 
the actual prescription of medication in a cross-sectional man-
ner for patients with ED in the United States, showed that urol-
ogists prescribed with the highest frequency. In present study, 
the result showed that 46.4% of physicians in the urology de-
partment had prescribed PDE5Is, whereas 33% of the endocri-
nology department had prescribed PDE5Is. In the case of pri-
mary physicians, it is considered that PDE5Is would be pre-
scribed in other departments at a higher frequency than the 
PDE5Is prescription ratio of a medical center. Nonetheless, this 
result requires identification of the cause of ED by performing a 
medical and psychosexual history with the use of validated in-
struments such as the IIEF at the basic diagnostic workup with 
subsequent physical examination and laboratory tests [17]. Be-
cause Korean linguistic validation has been completed of ques-
tionnaires such as the IIEF and IIEF-5, such instruments can be www.einj.or.kr    221
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effective tools for history taking [18,19].
  Our study is an observational study that investigated the pre-
scription frequencies of alpha-blockers and PDE5Is of each 
clinical department from 3 different general medical centers. 
Although it was not possible to take into consideration the per-
formance of the first medical examination and urological con-
sultation in the subjected data, it was identified that alpha-
blockers and PDE5Is were prescribed often by departments 
other than the urology department. This is the first domestic 
report of these data. Also, studies of practical patterns of the 
family medicine department or the actual primary physicians 
are lacking. Thus, the implications of the present results are var-
ious.
  In conclusion, alpha-blockers and PDE5Is are the most 
widely used drugs in the urology department, requiring spe-
cialized knowledge for their prescription. However, in this 
study, it was found that these drugs were being prescribed at a 
high frequency by other departments. Given the fact that a high 
ratio of the prescriptions were from other departments, it ap-
pears that far more specialized medical care by urologists is re-
quired in the treatment of LUTS/BPH and ED.
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